Devonian Health Group Inc. (DVHGF)
USD 0.13
(-6.29%)
USD 0.13
(-6.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.38 Million CAD | -194.27% |
| 2022 | 1.47 Million CAD | -70.12% |
| 2021 | 4.93 Million CAD | 30.72% |
| 2020 | 3.77 Million CAD | -10.03% |
| 2019 | 4.19 Million CAD | 46.1% |
| 2018 | 2.86 Million CAD | 172.0% |
| 2017 | 1.05 Million CAD | -78.71% |
| 2016 | 4.95 Million CAD | -7.12% |
| 2015 | 5.33 Million CAD | 8430.68% |
| 2014 | -64.02 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.27 Million CAD | 8.17% |
| 2024 Q2 | 2.7 Million CAD | 311.72% |
| 2024 Q3 | -1.32 Million CAD | -149.07% |
| 2023 Q1 | -2.66 Million CAD | -280.77% |
| 2023 Q2 | -2.27 Million CAD | 14.46% |
| 2023 FY | -1.38 Million CAD | -194.27% |
| 2023 Q3 | -1.44 Million CAD | 36.39% |
| 2023 Q4 | -1.38 Million CAD | 4.16% |
| 2022 Q2 | -4.84 Million CAD | -208.12% |
| 2022 Q4 | 1.47 Million CAD | 134.76% |
| 2022 FY | 1.47 Million CAD | -70.12% |
| 2022 Q1 | 4.47 Million CAD | -9.15% |
| 2022 Q3 | -4.23 Million CAD | 12.49% |
| 2021 Q1 | 4.4 Million CAD | 16.88% |
| 2021 FY | 4.93 Million CAD | 30.72% |
| 2021 Q4 | 4.93 Million CAD | 11.8% |
| 2021 Q3 | 4.4 Million CAD | 9.48% |
| 2021 Q2 | 4.02 Million CAD | -8.63% |
| 2020 Q3 | 4.66 Million CAD | 4.81% |
| 2020 Q4 | 3.77 Million CAD | -19.17% |
| 2020 Q2 | 4.45 Million CAD | -4.97% |
| 2020 FY | 3.77 Million CAD | -10.03% |
| 2020 Q1 | 4.68 Million CAD | 11.75% |
| 2019 Q4 | 4.19 Million CAD | 5.85% |
| 2019 Q2 | 3.13 Million CAD | -13.35% |
| 2019 FY | 4.19 Million CAD | 46.1% |
| 2019 Q1 | 3.61 Million CAD | 26.16% |
| 2019 Q3 | 3.96 Million CAD | 26.28% |
| 2018 Q3 | 3.09 Million CAD | 42.86% |
| 2018 Q4 | 2.86 Million CAD | -7.34% |
| 2018 FY | 2.86 Million CAD | 172.0% |
| 2018 Q2 | 2.16 Million CAD | 42.38% |
| 2018 Q1 | 1.52 Million CAD | 44.32% |
| 2017 FY | 1.05 Million CAD | -78.71% |
| 2017 Q4 | 1.05 Million CAD | -77.3% |
| 2017 Q3 | 4.64 Million CAD | -12.4% |
| 2017 Q1 | 5.41 Million CAD | -1.09% |
| 2017 Q2 | 5.3 Million CAD | -1.98% |
| 2016 Q3 | 5.25 Million CAD | 3976.29% |
| 2016 FY | 4.95 Million CAD | -7.12% |
| 2016 Q2 | -135.59 Thousand CAD | 30.47% |
| 2016 Q1 | -195.02 Thousand CAD | 22.43% |
| 2016 Q4 | 5.47 Million CAD | 4.08% |
| 2015 Q1 | -283.52 Thousand CAD | 0.0% |
| 2015 Q3 | -252.74 Thousand CAD | 0.0% |
| 2015 FY | 5.33 Million CAD | 8430.68% |
| 2015 Q4 | -251.4 Thousand CAD | 0.53% |
| 2014 FY | -64.02 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 220.191% |
| CSL Limited | 10.52 Billion USD | 100.013% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 108.81% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 133.723% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 445.582% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 103.245% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 77.973% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 249.777% |
| Mesoblast Limited | 55.85 Million USD | 102.486% |
| Marizyme, Inc. | 18.56 Million USD | 107.479% |
| Genus plc | 190.6 Million USD | 100.729% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 162.112% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 214.402% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 304.223% |
| ContraFect Corporation | -6.02 Million USD | 76.955% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1131.437% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | 7.67 Million USD | 118.105% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 125.241% |
| MultiCell Technologies, Inc. | 90.04 USD | 1542432.297% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -89.204% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 110.727% |
| EV Biologics, Inc. | 1.36 Million USD | 201.516% |
| Q BioMed Inc. | 4.06 Million USD | 134.205% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 104.545% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 237.808% |
| Biomind Labs Inc. | 711.4 Thousand USD | 295.208% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 110.844% |
| Skye Bioscience, Inc. | -5.72 Million USD | 75.728% |
| SQZ Biotechnologies Company | -36.23 Million USD | 96.168% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1093.331% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 124.586% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 161.935% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 7090.064% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 323.136% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 101.265% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 261.433% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 163.067% |
| GB Sciences, Inc. | 1.74 Million USD | 179.477% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -655.608% |
| argenx SE | -2.02 Billion USD | 99.932% |
| HST Global, Inc. | 96.79 Thousand USD | 1534.728% |
| Halberd Corporation | 144.72 Thousand USD | 1059.582% |
| Enzolytics Inc. | 981.65 Thousand USD | 241.467% |
| Resverlogix Corp. | 6.45 Million USD | 121.527% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -106.32% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 103.197% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 102.294% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 97.046% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 169.457% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 119.64% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 486.065% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 151.27% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 84.29% |
| AVAX Technologies, Inc. | -5.9 Million USD | 76.475% |
| ONE Bio Corp. | 9.04 Million USD | 115.362% |
| Zenith Capital Corp. | 10.06 Thousand USD | 13898.847% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.869% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 792.861% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 158.202% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 944.158% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -7481.155% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 773.425% |
| Agentix Corp. | 37.63 Thousand USD | 3790.351% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -253.1 Thousand USD | -448.678% |
| Helix BioMedix, Inc. | -2.57 Million USD | 45.965% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 106.849% |
| BioStem Technologies, Inc. | 4.47 Million USD | 131.054% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 790.032% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -105908.855% |
| LadRx Corporation | -2.03 Million USD | 31.808% |
| Cell Source, Inc. | 9.23 Million USD | 115.042% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -6704.763% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 318.638% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 318.638% |
| NovAccess Global Inc. | 2.17 Million USD | 163.747% |
| Affymax, Inc. | -5.59 Million USD | 75.188% |
| Itoco Inc. | 228.3 Thousand USD | 708.272% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1121.197% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 128.015% |
| CytoDyn Inc. | 20.26 Million USD | 106.854% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -214539.258% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -14883.438% |
| Qrons Inc. | 351.42 Thousand USD | 495.165% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 118.021% |
| SYBLEU INC | 473.71 Thousand USD | 393.155% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -456.332% |
| Rebus Holdings, Inc. | 305 Thousand USD | 555.317% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 131.158% |
| Mobile Lads Corp. | 484.23 Thousand USD | 386.787% |
| International Stem Cell Corporation | 2.59 Million USD | 153.618% |
| Bioxytran, Inc. | 1.89 Million USD | 173.132% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 2325.043% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 163.676% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 140.44% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 116.237% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 279.744% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -11.097% |
| Neutra Corp. | 52.18 Thousand USD | 2761.038% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 44.206% |
| PureTech Health plc | -167.19 Million USD | 99.169% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -467.036% |
| IXICO plc | -4.44 Million USD | 68.755% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 110.505% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 102.532% |
| CSL Limited | 10.52 Billion USD | 100.013% |
| Cellectis S.A. | -43.81 Million USD | 96.831% |